Stock 301075 TIBET DUO RUI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Tibet Duo Rui Pharmaceutical Co., Ltd.

Equities

301075

CNE100004RW5

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
16.3 CNY +6.19% Intraday chart for Tibet Duo Rui Pharmaceutical Co., Ltd. -11.75% -38.88%
05-07 Tranche Update on Tibet Duo Rui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 5, 2024. CI
04-30 Tibet Duo Rui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 5, 2024, has closed with 1,044,500 shares, representing 1.31% for CNY 20.98 million. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Tibet Duo Rui Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 31 May 2024
CI
Tibet Duo Rui Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023
CI
Tranche Update on Tibet Duo Rui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 5, 2024.
CI
Tibet Duo Rui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 5, 2024, has closed with 1,044,500 shares, representing 1.31% for CNY 20.98 million.
CI
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shiyan Jiaruihe Traditional Chinese Medicine Co., Ltd announced that it expects to receive CNY 7 million in funding from Tibet Duo Rui Pharmaceutical Co., Ltd., Shiyan Shenqi Agricultural Development Co., Ltd.
CI
Tranche Update on Tibet Duo Rui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 5, 2024.
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 30 million worth of its shares.
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
CI
Jiangxi Kelun Pharmaceutical Co., Ltd. and Hubei Yinuokang Medical Technology Co., Ltd. agreed to acquire 49% stake in Wuhan Quanruinuo Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co.,Ltd. for CNY 0.
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Hongxi Medical Technology Co., Ltd. for CNY 0.
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. completed the acquisition of 38.125% stake in Hubei Xinchengda Chemical Co., Ltd. from Wuhan Shengxiang Chemical Co., Ltd. and Wuhan Jinshengxing Automatic Control Engineering Co., Ltd.
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. entered into a Investment Intent Agreement to acquire 38.125% stake in Hubei Xinchengda Chemical Co., Ltd. from Wuhan Shengxiang Chemical Co., Ltd. and Wuhan Jinshengxing Automatic Control Engineering Co., Ltd. for CNY 30.5 million.
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Tibet Duo Rui Pharmaceutical Co.,Ltd. Announces Directorate Appointments
CI
Hubei Tianji Pharmaceutical Co., Ltd. announced that it expects to receive CNY 60 million in funding from Tibet Duo Rui Pharmaceutical Co.,Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 301075 Stock
  4. News Tibet Duo Rui Pharmaceutical Co., Ltd.